Immunocontraceptives: How far from reality?

Lekhwani, Seema; Vaswani, ND; Ghalaut, Veena Singh; Shanker, Vijay; Singh, Ragini

Immunocontraceptives: How far from reality?

Authors

¹ Department of Biochemistry, Pt. B. D. Sharma PGIMS, Rohtak, Haryana, India

² Department of Pediatrics, Pt. B. D. Sharma PGIMS, Rohtak, Haryana, India

³ Department of Pathology, Pt. B. D. Sharma PGIMS, Rohtak, Haryana, India

Abstract

Despite high expectations of safer, effective, economical, longer acting contraceptives, to date, there are no licensed contraceptive vaccines available in the market. Nevertheless, a role for vaccines undoubtedly exists as an aid to birth spacing and as a nonsurgical means of generating sterility. The research concerned in the area so far has been successful on the feline population, with room still for exhaustive studies on humans. The future of contraceptive vaccines holds great promise in terms of comfort, price, efficacy, rare complications, and possibly nonselective action on animal populations as well as on humans. This brief review deals with the basic aspects of immunocontraceptives along with the efforts done so far. There is a need for further research in aspects involving the rate of evolution of contraception resistance based on genetics, resistance phenotypes, or cross generation effects. Gonadotropin-releasing hormone and luteinizing-hormone have not been investigated in humans, as both reported impotency in animals; the follicle-stimulating hormone has been shown to cause oligospermia; zona pellucida has also not been studied in humans as it causes irreversible oophoritis, while the sperm has the potential for success in humans based on the data from immunoreproductive studies. Even as the position of the human chorionic gonadotropin vaccine looks hopeful, research on other possible targets continue with an eventual aim of discovering a vaccine that is more immunogenically effective.

Keywords

References

1.	World POPClock Projection. US Census Bureau. Available from: http://www.census.gov/main/www.popclock.html. [Accessed on 2011 Jan 1].
2.	WHO/63 News Release. Nov 1, 2006. Available from: http://www.whqlibdoc.who.int/press_release/2006/PR_63.pdf. [Last accessed on 2013 Feb 19].
3.	Sharma RS, Rajalakshmi M, Jeyaraj DA. Current status of fertility control methods in India. J Biosci 2001;26:391-405.
4.	Feng H, Sandlow J, Sparks A, Sandra A. Development of an immun ocontraceptive vaccine: Current status. J Reprod Med 1999;44:759-65.
5.	Gupta SK. Status of immunodiagnosis and immunocontraceptive vaccines in India. Adv Biochem Engin/Biotechnol 2003;85:181-214.
6.	Kumar TCA. Development of immunocontraceptives: An introduction. Hum Reprod Update 1997;3:299-300.
7.	Ferro VA, Mordini. Peptide vaccines in immunocontraception. Curr Opin Mol Ther 2004;6:83-9.
8.	Aitken RJ. Immunocontraceptive vaccines for human use. J Reprod Immunol 2002;57:273-87.
9.	Gupta SK, Gupta N, Suman P, Choudhury S, Prakash K, Gupta T, et al. Zona pellucid-based contraceptive vaccines for human and animal utility. J Reprod Immunol 2011;88:240-6.
10.	Jones WR. Contraceptive vaccines. Baillieres Clin Obstet Gynaecol 1996;10:69-86.
11.	Naz RK. Contraceptive vaccines: Success, status and future perspective. Am J Reprod Immunol 2011;66:2-4.
12.	Landsteiner K. To knowing that sera which specifi cally acts on blood corpuscles. Int J Med Microbiol 1899;25:546-9.
13.	Mtchnikoff E. Etudes sur la resorption de cellule. Ann Inst Pasteur 1899;13:737-79.
14.	Baskin MJ. Temporary sterilization by injection of human spermatozoa: A preliminary report. Am J Obstet Gynecol 1932;24:892-7.
15.	Peter JD. How far from a hormone-based contraceptive vaccine? J Reprod Immunol 2004;62:69-78.
16.	Ferro VA. Current advances in antifertility vaccines for fertility control and noncontraceptive applications. Expert Rev Vaccines 2002;1:443-52.
17.	Puri CP, Gopalkrishnan K, Iyer KS. Constraints in the development of contraceptives for men. Asian J Androl 2000;2:179-90.
18.	Talwar GP. Fertility regulating and immunotherapeutic vaccines reaching human trials stage. Hum Reprod Update 1997;3:301-10.
19.	McLaughlin EA, Holland MK, Aitken RJ. Contraceptive vaccines. Expert Opin Biol Ther 2003;3:829-41.
20.	Talwar GP, Hingorani V, Kumar S, Banerjee A, Shahani SM, Krishna U, et al. Phase I clinical trials with three formulations of anti-chorionic gonadotropin vaccine. Contraception 1990;41:301-16.
21.	Thau R, Croxatto H, Luukkainen T, Alvarez F, Brache V, Sunbdaram K, et al. Reproductive Immunology. In: Mettler L, Billington WD, editors. Amsterdam: Elsevier; 1989. p. 237-44.
22.	Stevens VC, Powell JE, Lee AC, Griffin PD. Antifertility effects of female baboons with C-terminal peptides of the beta-subunit of human chorionic gonadotropin. Fertil Steril 1981;36:98-105.
23.	Stevens VC. Progress in the development of human chorionic gonadotropin antifertility vaccines. Am J Reprod Immunol 1996;35:148-55.
24.	Stevens VC, Jones WR. Reproductive Immunology. In: Isojima S, Billington WD, editors. Amsterdam: Elsevier; 1983. p. 233-7.
25.	Jones WR. Contraception. Baillière's Clin Obstet Gynaecol 1992;6:629-40.
26.	Gupta A, Pal R, Ahlawat S, Bhatia P, Singh O. Enhanced immunogenicity of a contraceptive vaccine using diverse synthetic carriers with permissible adjuvant. Vaccine 2001;19:3384-9.
27.	Naz RK, Gupta SK, Gupta JC, Vyas HK, Talwar AG. Recent advances in contraceptive vaccine development: A mini-review. Human Reprod 2005;20:3271-83.
28.	Talwar GP, Singh O, Gupta SK, Hasnain SE, Pal R, Majumdar SS, et al. The HSD-hCG vaccine prevents pregnancy in women: Feasibility study of a reversible safe contraceptive vaccine. Am J Reprod Immunol 1997;37:153-60.
29.	Moudgal NR, Sairam MR, Krishnamurthy H, Khan H. Immunization of male bonnet monkeys (M. radiata) with a recombinant FSH receptor preparation affects testicular function and fertility. Endocrinology 1997;138:3065-8.
30.	Karande AA, Adiga PR. Early pregnancy termination in rats immunized with denatured thiamine carrier protein in pregnant rats by using monoclonal antibodies. Int J Biochem Biophys 1991;28:467-70.
31.	Singh M, Singh O, Talwar GP. Biodegradable delivery system for a birth control vaccine: Immunogenicity studies in rats and monkeys. Pharm Res 1995;12:1796-800.
32.	Lemons AR, Naz RK. Contraceptive vaccines targeting factors involved in establishment of pregnancy. Am J Reprod Immunol 2011;66:13-25.
33.	Gupta SK. Update on zona pellucida glycoproteins based contraceptive vaccine. J Reprod Immunol 2004;62:79-89.
34.	Covey DC, Moore DE. Current trends in antifertility vaccine research. West J Med 1985;142:197-202.
35.	Shivers CA, Dudkiewicz AB, Franklin LE. Inhibition of sperm-egg interaction by specific antibody. Science 1972;178:1211-3.
36.	Kirkpatrick J, Turner JW, Liu IK, Fayrer-Hosken R, Rutberg AT. Case studies in wildlife immunocontraception: Wild and feral equids and white-tailed deer. Reprod Fertil Dev 1997;9:105-10.
37.	Sacco AG. Immunocontraception: Consideration of the zona pellucid as a target antigen. Obstet Gynecol Annn 1981;10:1-26.
38.	Gupta SK. Update on zona pellucida glycoproteins based contraceptive vaccine. J Reprod Immunol 2004;62:79-89.
39.	Naz RK. Development of genetically engineered human sperm immunocontraceptives. J Reprod Immunol 2009;83:145-50.
40.	Shaha C, Suri A, Talwar GP. Identification of sperm antigens that regulate fertility. Int J Androl 1988;11:479-91.
41.	Edwards RG. Immunological control of fertility in female mice. Nature 1964;203:50-3.
42.	Baskin MJ. Temporary sterilization by injection of human spermatozoa: A preliminary report. Am J Obstet Gynecol 1932;24:892-7.
43.	Ohl D, Naz RK. Infertility due to antisperm antibodies. J Urol 1995;46:591-602.
44.	Naz RK. Applications of sperm antigens in immunocontraception. Frontiers in Bioscience 1996;1:87-95.
45.	Naz RK, Rowan S. Update on male contraception. Curr Opin Obstet Gynecol 2009;21:265-9.
46.	Naz RK. Status of contraceptive vaccines. Am J Reprod Immunol 2009;61:11-8.
47.	Naz RK. Antisperm vaccine for contraception. Am J Reprod Immunol 2005;54:378-83.
48.	Zhu X, Naz RK. Fertilization antigen-1: cDNA cloning, testis-specific expression, and immunocontraceptive effects. Proc Natl Acad Sci USA 1997;94:4704-9.
49.	Naz RK, Zhu X, Kadam AL. Identification of human sperm peptide sequence involved in egg binding for immunocontraception. Biol Reprod 2000;62:318-24.
50.	Naz RK, Zhu X, Kalam AL. Cloning and sequencing cDNA encoding for a novel human testis-specific contraceptive vaccinogen: Role of immunocontraception. Mol Reprod Dev 2001;60:116-27.
51.	Santhanam R, Naz RK. Novel human testis-specific cDNA: Molecular cloning, expression and immunological effects of the recombinant protein. Mol Reprod Dev 2001;60:1-12.
52.	O'Hearn PA, Liang ZG, Bambra CS, Goldberg E. Colinear synthesis of an antigen-specific B-cell epitope with a promiscuous tetanus toxin T-cell epitope: A synthetic peptide immunocontraceptive. Vaccine 1997;15:1761-6.
53.	O'Rand MG, Beavers J, Widgren E, Tung K. Inhibition of fertility in female mice by immunization with a B-cell epitope, the synthetic sperm peptide, P10G. J Reprod Immunol 1993;25:89-102.
54.	Lea JA, van Lierop MJC, Widgren EE, Grootenhuic A, Wen Y, van Duin M, et al. A chimeric sperm peptide induced antibodies and strain-specific reversible infertility in mice. Biol Reprod 1998;59:527-36.
55.	Hardy CM, Mobbs JK. Expression of recombinant mouse sperm protein sp56 and assess ment of its potential for use as an antigen in an immunocontraceptive vaccine. Mol Reprod Dev 1999;52:527-36.
56.	O'Rand MG, Widgren EE, Sivashanmugam P, Richardson RT, Hall SH, French FS, et al. Reversible immunocontraception in male monkeys immunized with Eppin. Science 2004;306:1189-90.
57.	Inoue N, Ikawa M, Isotani A, Okabe M. The immunoglobin superfamily protein Izumo is required for sperm to fuse with eggs. Nature 2005;434:234-8.

Advanced Biomedical Research